Christopher Stokoe
Texas Oncology
9 Papers
49 Citations
Christopher Stokoe is an academic researcher from Texas Oncology. The author has contributed to research in topics: Docetaxel & Breast cancer. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
Louis Fehrenbacher,Reena S. Cecchini,Charles E. Geyer,Priya Rastogi,Joseph P. Costantino,James N. Atkins,John Crown,Jonathan Polikoff,Jean Francois Boileau,Louise Provencher,Christopher Stokoe,Timothy David Moore,André Robidoux,Patrick J. Flynn,Virginia F. Borges,Kathy S. Albain,Sandra M. Swain,Soonmyung Paik,Eleftherios P. Mamounas,Norman Wolmark +19 more
TL;DR: The addition of trastuzumab to CRx did not improve IDFS, distant recurrence-free interval, or OS in women with non-HER2-overexpressing IBC and does not benefit women without IHC 3+ or FISH ratio-amplified breast cancer.
331
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
Stephen E. Jones,Rufus P. Collea,Devchand Paul,Scot Sedlacek,Anne Favret,Ira Gore,Deborah Lindquist,Frankie A. Holmes,Mary Ann K Allison,Barry Don Brooks,Raul M Portillo,Svetislava J. Vukelja,Michael S. Steinberg,Christopher Stokoe,Maria W Crockett,Yunfei Wang,Lina Asmar,Nicholas J. Robert,Joyce O'Shaughnessy +18 more
TL;DR: A short, four-cycle regimen of docetaxel and cyclophosphamide combined with trastuzumab could be an option for adjuvant treatment of women with lower risk HER2-amplified early breast cancer, irrespective of TOP2A status.
The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer
Stephen E. Jones,Christopher Stokoe,Mark Sborov,Marcus Braun,Sukumar Ethirajan,Leila Kutteh,J. Pippen,Mrugesh Patel,Devchand Paul,Joanne L. Blum,Frankie A. Holmes,Mark C. Myron,J. Cantrell,Nichole L. Hartung,Regan M. Look,Enrico Di Salle,Jennifer C. Davis,Des Ilegbodu,Lina Asmar +18 more
TL;DR: More bone loss occurred during the first 12 months of treatment with E compared with T, but by 2 years the differences were less apparent and bone loss with E had slowed.
28
A Phase II Trial of Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer Who Have Received Prior Taxane Therapy
John Pippen,Anthony D. Elias,Marcus A. Neubauer,Christopher Stokoe,LaTrice G. Vaughn,Yanping Wang,Mauro Orlando,Oluwatoyin O. Shonukan,Joseph Muscato,Joyce O'Shaughnessy,Julie R. Gralow +10 more
TL;DR: Pemetrexed/gemcitabine given on a 21-day or 14- day schedule is active in patients with advanced breast cancer previously treated with taxanes, and a 14-day schedule appears to result in fewer serious toxicities.
12
Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.
John Pippen,Devchand Paul,Christopher Stokoe,Joanne L. Blum,Lea Krekow,Frankie A. Holmes,Deborah Lindquist,Scot Sedlacek,Ragene Rivera,R. J. Brooks,Svetislava J. Vukelja,Kristi McIntyre,Christine Lopez-Diaz,Joyce A. O'Shaughnessy +13 more
TL;DR: Exploratory Ki-67 analyses suggested benefit of X in more highly proliferative tumors, reflecting the importance of pt selection in adjuvant trials.
9